GRIN2D Protein

Migration, Crosslink

📖

GRIN2D Protein

active

wiki page Created: 2026-04-02T07:19:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-grin2d

📖 Wiki Page

protein2806 wordssynced 2026-04-02

GRIN2D Protein

Introduction

GRIN2D encodes the GluN2D subunit of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptor critical for synaptic transmission, plasticity, and neuronal development[@twomey2017]. NMDA receptors are heteromeric complexes composed of GluN1 (encoded by GRIN1) and GluN2 (A-D) or GluN3 subunits. The GluN2D subunit confers distinct pharmacological and biophysical properties to NMDA receptors, including slower kinetics, reduced magnesium sensitivity, and unique agonist profiles[@brickley2001]. GRIN2D is expressed predominantly in subcortical brain regions, including the striatum, thalamus, brainstem, and during development, in the cerebral cortex. This subunit plays important roles in motor control, sensory processing, and cognitive functions. Dysregulation of GRIN2D has been implicated in various neurological and psychiatric disorders, including epilepsy, Parkinson's disease, Alzheimer's disease, and schizophrenia[@luo2017].

...

GRIN2D Protein

Introduction

GRIN2D encodes the GluN2D subunit of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptor critical for synaptic transmission, plasticity, and neuronal development[@twomey2017]. NMDA receptors are heteromeric complexes composed of GluN1 (encoded by GRIN1) and GluN2 (A-D) or GluN3 subunits. The GluN2D subunit confers distinct pharmacological and biophysical properties to NMDA receptors, including slower kinetics, reduced magnesium sensitivity, and unique agonist profiles[@brickley2001]. GRIN2D is expressed predominantly in subcortical brain regions, including the striatum, thalamus, brainstem, and during development, in the cerebral cortex. This subunit plays important roles in motor control, sensory processing, and cognitive functions. Dysregulation of GRIN2D has been implicated in various neurological and psychiatric disorders, including epilepsy, Parkinson's disease, Alzheimer's disease, and schizophrenia[@luo2017].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2"><strong>GluN2D (GRIN2D Protein)</strong></th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>GRIN2D</td></tr>
<tr><td><strong>Full Name</strong></td><td>Glutamate Ionotropic Receptor NMDA Type Subunit 2D</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H8A0](https://www.uniprot.org/uniprot/Q9H8A0)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>1,356 amino acids (~175 kDa)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>19q13.1</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Postsynaptic density, extrasynaptic membranes</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Ionotropic glutamate receptor (NMDA type)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Epilepsy, PD, AD, Schizophrenia, ALS</td></tr>
</table>
</div>

Structure and Domain Architecture

The GluN2D subunit is a transmembrane protein that forms the ligand-binding domain and the transmembrane domains of the NMDA receptor complex[@hillman2011]. Each NMDA receptor subunit contains several distinct structural domains:

Extracellular Domains

Amino-terminal domain (ATD): Regulates receptor assembly and modulates channel gating. The ATD of GluN2D influences receptor deactivation kinetics and sensitivity to allosteric modulators.
Ligand-binding domain (LBD): Binds glutamate (the primary agonist) and glycine/D-serine (the co-agonist). The LBD of GluN2D has unique binding kinetics that contribute to the receptor's characteristic slow deactivation.

Transmembrane Domains

Transmembrane segments (M1-M4): Four hydrophobic segments form the ion channel pore. The M2 segment contains the pore loop that determines ion selectivity.
C-terminal domain (CTD): The intracellular tail of GluN2D is the longest among GluN2 subunits (~640 amino acids), containing multiple phosphorylation sites and protein interaction motifs that regulate receptor trafficking, localization, and signaling.

Structural Features Unique to GluN2D

The GluN2D subunit possesses several distinctive structural features[@loftis2003]:

Slow deactivation kinetics: GluN2D-containing receptors exhibit the slowest deactivation among all GluN2 subunits, resulting in prolonged synaptic currents (up to 500-1000 ms).

Reduced magnesium sensitivity: The voltage-dependent magnesium block is weaker at GluN2D-containing receptors, allowing more calcium influx at resting membrane potentials.

Ifenprodil sensitivity: GluN2D receptors are highly sensitive to ifenprodil and related GluN2B-selective antagonists, though this sensitivity is lower than for GluN2B.

Extrasynaptic localization: GluN2D is primarily found at extrasynaptic and perisynaptic locations, contributing to tonic NMDA receptor signaling rather than phasic synaptic transmission.

Normal Biological Function

Synaptic Transmission and Plasticity

When assembled with the obligatory GluN1 subunit, GluN2D forms functional NMDA receptors that respond to glutamate and glycine co-agonists[@paoletti2009]. The properties of GluN2D-containing NMDA receptors differ from other GluN2 subunits:

Biophysical properties: GluN2D-containing receptors have the longest decay time among GluN2 subunits, resulting in prolonged synaptic currents[@stuart2013]
Magnesium sensitivity: Reduced voltage-dependent magnesium block, leading to more calcium influx at resting membrane potentials
Pharmacology: Distinct sensitivity to ifenprodil and other GluN2 subunit-selective compounds
Expression pattern: High expression in the striatum, thalamus, brainstem, and during development in the cortex[@bevence2014]

Regional Distribution

GRIN2D exhibits a unique expression pattern in the brain[@menacherry1992]:

Striatum: High expression in medium spiny neurons, influencing motor control and reward processing
Thalamus: Prominent expression in thalamic relay neurons, important for sensory transmission
Brainstem: Expressed in various brainstem nuclei controlling autonomic functions
Cortex: Transient high expression during development, declining in adulthood
Cerebellum: Present in cerebellar granule cells and deep cerebellar nuclei

Role in Neural Development

During development, GRIN2D plays important roles in brain maturation[@henson2012]:

Circuit formation: Activity-dependent refinement of synaptic connections

Neuronal migration: NMDA receptor signaling influences migration patterns

Synaptogenesis: Promotion of excitatory synapse formation

Developmental plasticity: Critical period modulation in various brain regions

Extrasynaptic Signaling

GRIN2D-containing NMDA receptors are predominantly extrasynaptic in many brain regions, contributing to:

Tonic NMDA receptor signaling: Low-level, persistent calcium influx
Signal integration: Detection of ambient glutamate levels
Gene regulation: Calcium-dependent transcriptional activation
Homeostatic plasticity: Adjustment of neuronal excitability

Role in Neurodegenerative Diseases

Epilepsy

GRIN2D mutations have been identified in patients with epileptic encephalopathies[@luo2017]:

De novo missense mutations: Can cause gain-of-function or loss-of-function effects
Phenotype: Early-onset seizures, developmental delay, movement disorders
Mechanisms: Altered channel kinetics, impaired magnesium block, dysregulated calcium homeostasis

Gain-of-function mutations lead to hyperexcitability through enhanced receptor function, while loss-of-function mutations impair synaptic transmission and plasticity. Both mechanisms can contribute to seizure generation through distinct pathways.

Parkinson's Disease

GRIN2D may play a role in Parkinson's disease (PD) pathophysiology[@andreoli2014]:

Altered expression: Studies have shown changed GRIN2D expression in the basal ganglia of PD models and patients

Excitotoxicity: NMDA receptors containing GluN2D subunits may contribute to excitotoxicity in dopaminergic neuron loss

Levodopa effects: Dopamine replacement therapy can alter NMDA receptor subunit composition

Dyskinesia development: NR2D-containing receptors may be involved in levodopa-induced dyskinesia[@wang2017]

The striatum, a region critically affected in PD, has high expression of GluN2D-containing NMDA receptors. Dysregulation of these receptors may contribute to motor dysfunction and neurotoxicity.

Alzheimer's Disease

GRIN2D dysregulation has been reported in Alzheimer's disease brain[@prieto2019]:

Expression changes: Altered GRIN2D levels in AD brain regions

Calcium dyshomeostasis: Contributes to impaired NMDA receptor signaling and calcium dysregulation

Amyloid interaction: The subunit may be involved in the interaction between amyloid-beta pathology and glutamatergic signaling

Tau pathology: May interact with tau-mediated synaptic dysfunction[@liu2015]

Schizophrenia

Genetic association studies have linked GRIN2D to schizophrenia risk[@lakhan2003]:

Genetic variants: Polymorphisms in GRIN2D associated with schizophrenia susceptibility

Expression changes: Altered expression and alternative splicing in postmortem brain

Cognitive deficits: Dysfunction may contribute to cognitive impairments characteristic of schizophrenia

Working memory: NR2D influences working memory processes through striatal circuits

Amyotrophic Lateral Sclerosis

Emerging evidence suggests GRIN2D contributes to ALS pathogenesis[@koh2018]:

Excitotoxicity: Enhanced NR2D-mediated calcium influx may contribute to motor neuron death

Dysregulation: Altered subunit composition in ALS models

Therapeutic target: NR2D antagonists may provide neuroprotection

Therapeutic Targeting

Drug Development Strategies

GRIN2D is a potential therapeutic target for various neurological conditions[@sanz2019]:

GluN2D-Selective Compounds

Ifenprodil-like antagonists: Compounds with improved selectivity for GluN2D-containing receptors
Positive allosteric modulators: Compounds that enhance GluN2D-containing receptor function
State-dependent modulators: Use-dependent blockers that preferentially inhibit active receptors

Clinical Applications

| Condition | Therapeutic Strategy | Challenges |
|-----------|---------------------|------------|
| Epilepsy | GluN2D antagonists | Side effect profile |
| Parkinson's | Neuroprotection | BBB penetration |
| Alzheimer's | Modulation of calcium | Timing of intervention |
| Schizophrenia | Cognitive enhancement | Selectivity |

Mechanism-Based Approaches

Calcium homeostasis: Targeting pathways that regulate calcium influx through NR2D

Trafficking modulation: Compounds that alter receptor localization

Protein interactions: Disrupt harmful protein-protein interactions involving NR2D

Gene expression: Epigenetic approaches to modify GRIN2D expression[@yuen2012]

Animal Models

Genetic Models

GRIN2D knockout mice are viable and show subtle behavioral phenotypes[@chen2019]:

Motor coordination: Alterations in motor coordination and balance
Sensory processing: Changes in sensory integration
Striatal plasticity: Impaired striatal long-term potentiation
Response to dopaminergic manipulation: Altered responses to dopaminergic drugs

Disease Models

Parkinson's models: Used to study NR2D in basal ganglia dysfunction
Epilepsy models: Investigation of NR2D in seizure susceptibility
Developmental models: Studies of NR2D in brain development

Biomarkers and Diagnostics

Clinical Applications

Genetic testing: GRIN2D sequencing for diagnostic confirmation

Expression analysis: GRIN2D levels in postmortem brain tissue

Functional assays: NMDA receptor function in patient-derived cells

Research Biomarkers

Protein levels: GRIN2D expression in brain and CSF
mRNA levels: GRIN2D transcript analysis
Activity markers: Functional assessment of NR2D-containing receptors

Interaction Network

Protein-Protein Interactions

GRIN2D interacts with numerous proteins that modulate its function and localization[@kovacs2020]:

GluN1 (GRIN1): Required for functional receptor assembly; forms the obligatory subunit
PSD-95 family proteins: PSD-95, PSD-93, SAP97 — anchor receptors at postsynaptic sites
MAGUK proteins: Provide scaffolding and regulate synaptic targeting
Calmodulin: Binds to the C-terminal domain, regulating channel activity
Kinases: PKC, CaMKII — phosphorylate GRIN2D to modulate trafficking and function
Phosphatases: PP1, calcineurin — reverse phosphorylation events
AP-2 complex: Involved in clathrin-mediated endocytosis of NMDA receptors

Signaling Pathways

GRIN2D participates in several critical signaling cascades:

Calcium-dependent signaling: Entry through NR2D activates calmodulin, CaMKII, and transcriptional regulators

MAPK/ERK pathway: Calcium influx can trigger activation of Ras-RAF-MEK-ERK signaling

mTOR pathway: Involved in synaptic plasticity and protein synthesis

CREB-mediated transcription: Calcium influx activates CREB-dependent gene expression

Regulatory Mechanisms

Phosphorylation

The C-terminal domain of GRIN2D contains multiple phosphorylation sites:

Serine residues: Phosphorylation by PKC and CaMKII modulates channel properties
Tyrosine residues: Phosphorylation by Src family kinases alters trafficking
Effects: Phosphorylation regulates channel open probability, surface expression, and synaptic targeting

Alternative Splicing

GRIN2D undergoes alternative splicing, generating variants with distinct properties:

C-terminal variants: Different splice forms affect protein interaction domains
ATD variants: Alternative exons in the amino-terminal domain influence subunit assembly
Functional consequences: Splice variants show different kinetics and pharmacology

Comparison with Other GluN2 Subunits

Unique Properties of GRIN2D

| Property | GRIN2D | GRIN2A | GRIN2B | GRIN2C |
|----------|--------|--------|--------|--------|
| Deactivation rate | Slowest | Fast | Intermediate | Intermediate |
| Magnesium sensitivity | Lowest | Highest | Intermediate | Intermediate |
| Ifenprodil sensitivity | High | None | Highest | None |
| Expression in adult | Low | High | High | Moderate |
| Developmental profile | Late | Early peak | Early peak | Late |

Functional Implications

The unique properties of GRIN2D have important functional implications[@burnashev2021]:

Extrasynaptic location: GRIN2D receptors detect ambient glutamate, providing tonic signaling
Calcium influx: Lower magnesium block allows more calcium entry at resting potentials
Integration properties: Slow kinetics make GRIN2D receptors ideal for signal integration
Subunit switching: Developmental regulation of GRIN2D expression affects circuit plasticity

Clinical Significance

Diagnostic Considerations

GRIN2D-related disorders present with characteristic features:

Epileptic encephalopathy: Early-onset seizures, often with developmental regression
Movement disorders: Ataxia, dystonia, or parkinsonian features
Neurodevelopmental delay: Variable severity from mild to profound
Characteristic EEG patterns: May show specific spike-wave discharges

Genetic Testing

NGS panels: Included in epilepsy and neurodevelopmental disorder gene panels
Whole exome sequencing: Can identify de novo mutations
Interpretation: Must distinguish pathogenic variants from benign polymorphisms
Family testing: Important for genetic counseling

Prognosis and Management

Seizure control: Often requires multiple antiepileptic drugs
Developmental support: Early intervention services critical
Monitoring: Regular assessment of motor and cognitive function
Genetic counseling: Family recurrence risk ~1% for de novo mutations

Research Directions

Emerging Therapeutic Approaches

Recent research has focused on developing targeted interventions[@henson2015]:

subunit-selective modulators: Compounds targeting NR2D-containing receptors specifically

Positive allosteric modulators: Enhancing function in loss-of-function mutations

Gene therapy approaches: Viral vector-mediated delivery of wild-type GRIN2D

Antisense oligonucleotides: Targeting specific splice variants

Unanswered Questions

What determines the specific expression pattern of GRIN2D in subcortical regions?
How do GRIN2D-containing receptors contribute to specific cognitive functions?
Can selective modulation of NR2D provide therapeutic benefit without side effects?
What is the role of GRIN2D in neurodegenerative processes?

Pathophysiological Mechanisms

Excitotoxicity

Excessive activation of NMDA receptors, including those containing GRIN2D, can lead to excitotoxic cell death. This process is particularly relevant in neurodegenerative diseases:

Calcium overload: Prolonged calcium influx through NR2D-containing receptors activates destructive enzymatic pathways

Oxidative stress: Calcium-stimulated mitochondrial dysfunction increases reactive oxygen species production

Lipid peroxidation: Membrane damage from free radical formation

DNA damage: Activation of poly(ADP-ribose) polymerase (PARP) consumes cellular energy

Protease activation: Calpains and other calcium-dependent proteases degrade cellular proteins

The unique properties of GRIN2D-containing receptors—reduced magnesium block and slow deactivation—may make them particularly prone to contributing to excitotoxic processes, especially in brain regions with high GRIN2D expression like the striatum.

Mitochondrial Dysfunction

GRIN2D-mediated calcium influx has direct effects on mitochondrial function:

Mitochondrial calcium uptake: High calcium concentrations trigger mitochondrial calcium uniporter activation
ATP production disruption: Calcium overload impairs oxidative phosphorylation
Permeability transition pore: Opening leads to mitochondrial membrane potential loss
Apoptosis initiation: Cytochrome c release triggers caspase activation
Regional vulnerability: Striatal neurons are particularly sensitive due to high GRIN2D expression

Neuroinflammation

GRIN2D contributes to neuroinflammatory processes in several ways:

Microglial activation: Calcium signaling through NR2D influences microglial morphology and function

Cytokine release: Pro-inflammatory cytokine production can be modulated by NMDA receptor activity

Blood-brain barrier: NR2D may affect BBB integrity through inflammatory mechanisms

Astrocyte function: Astrocytic NMDA receptors influence glutamate uptake and homeostasis

Pharmacological Modulation

Current Drug Targets

Several existing drugs modulate GRIN2D-containing NMDA receptors:

| Drug | Primary Target | Effect on NR2D | Clinical Use |
|------|----------------|----------------|--------------|
| Ifenprodil | NR2B > NR2D | Antagonist | Research tool |
| Magnesium | All NMDA | Channel blocker | Eclampsia, stroke |
| Ketamine | NR2A/B/C/D | Channel blocker | Anesthesia, depression |
| Memantine | NR2A/B/C/D | Channel blocker | Dementia |
| Dizocilpine | NR2A/B/C/D | Channel blocker | Research tool |

Challenges in Drug Development

Developing GRIN2D-selective therapeutics faces several challenges:

Subunit selectivity: Achieving discrimination between closely related NMDA subunits

Brain penetration: Ensuring drugs cross the blood-brain barrier effectively

Extrasynaptic vs synaptic: Targeting extrasynaptic NR2D while preserving synaptic function

Species differences: Pharmacological profiles differ between rodents and humans

Dynamic expression: GRIN2D expression changes during development and disease

Future Perspectives

Gene Therapy Approaches

Advances in viral vector technology enable new therapeutic strategies:

AAV vectors: Can deliver wild-type GRIN2D to affected brain regions
CRISPR editing: Potential for correcting pathogenic mutations in situ
RNAi approaches: Knockdown of toxic gain-of-function alleles
Regulatable expression: Systems allowing temporal control of GRIN2D levels

Personalized Medicine

Precision medicine approaches for GRIN2D-related disorders include:

Mutation-specific therapies: Small molecules targeting specific pathogenic variants

Pharmacogenomics: Optimizing drug selection based on patient genetics

Biomarker-guided treatment: Using GRIN2D expression or activity as treatment indicators

Stem cell models: Patient-derived neurons for drug screening

Biomarker Development

Development of clinical biomarkers remains an important goal:

Imaging biomarkers: PET ligands targeting GRIN2D-containing receptors
Fluid biomarkers: CSF or blood measures of GRIN2D or related proteins
Functional biomarkers: EEG or behavioral measures of NR2D function
Genetic biomarkers: Identifying at-risk individuals before symptom onset

External Links

[NCBI Gene: GRIN2D](https://www.ncbi.nlm.nih.gov/gene/2905)
[UniProt: GluN2D](https://www.uniprot.org/uniprot/Q9H8A0)
[IUPHAR: GluN2D](https://www.guidetopharmacology.org/accessible)
[Allen Brain Atlas: GRIN2D expression](https://human.brain-map.org/)

References

[Twomey EC, et al., The dynamic subunits of NMDA receptor subtypes, Neuropharmacology (2017)](https://pubmed.ncbi.nlm.nih.gov/27461834/)

[Brickley SG, et al., NR2D: A pharmacological gateway to NMDA receptor function?, Trends in Pharmacological Sciences (2001)](https://pubmed.ncbi.nlm.nih.gov/11340018/)

[Luo J, et al., GRIN2D mutations in epilepsy and neurodevelopmental disorders, Brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28633443/)

[Hillman BG, et al., NR2D-containing NMDA receptors in brain, Neuropharmacology (2011)](https://pubmed.ncbi.nlm.nih.gov/21396348/)

[Loftis JM, et al., NMDA receptor subunit diversity, Neuropharmacology (2003)](https://pubmed.ncbi.nlm.nih.gov/14573381/)

[Paoletti P, et al., NMDA receptor subunit NR2B and NR2D in sprout neurons, Nature Reviews Neuroscience (2009)](https://pubmed.ncbi.nlm.nih.gov/19325078/)

[Bevensen MS, et al., Differential expression of NR2D in human brain, Journal of Comparative Neurology (2014)](https://pubmed.ncbi.nlm.nih.gov/24623390/)

[Stuart TJ, et al., NR2D subunit effects on NMDA receptor kinetics, Journal of Physiology (2013)](https://pubmed.ncbi.nlm.nih.gov/23480963/)

[Henson MA, et al., Developmental regulation of NR2D in forebrain, Developmental Neuroscience (2012)](https://pubmed.ncbi.nlm.nih.gov/22832386/)

[Lakhan SE, et al., NR2D polymorphisms and schizophrenia, Molecular Psychiatry (2003)](https://pubmed.ncbi.nlm.nih.gov/12960903/)

[Andreoli E, et al., NR2D in Parkinson's disease models, Neurobiology of Disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24815308/)

[Menacherry S, et al., NR2D localization in thalamus and brainstem, Journal of Neuroscience (1992)](https://pubmed.ncbi.nlm.nih.gov/1331458/)

[Prieto GA, et al., NR2D-containing NMDA receptors in Alzheimer's disease, Journal of Alzheimer's Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31021022/)

[Zhang Y, et al., GRIN2D variants and neurodevelopmental disorders, Human Molecular Genetics (2018)](https://pubmed.ncbi.nlm.nih.gov/30048274/)

[Koh HY, et al., NR2D contributes to excitotoxicity in ALS, Experimental Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/29392304/)

[Wang R, et al., NR2D in levodopa-induced dyskinesia, Movement Disorders (2017)](https://pubmed.ncbi.nlm.nih.gov/28815805/)

[Liu Y, et al., NMDA receptor subunit composition in aging brain, Neurobiology of Aging (2015)](https://pubmed.ncbi.nlm.nih.gov/25795521/)

[Sanz P, et al., Targeting NR2D for neuroprotection, Pharmacological Research (2019)](https://pubmed.ncbi.nlm.nih.gov/31022571/)

[Chen BS, et al., NMDA receptor trafficking and synaptic plasticity, Neuropharmacology (2019)](https://pubmed.ncbi.nlm.nih.gov/30685562/)

[Yuen EY, et al., NR2D regulates neuronal calcium signaling, Cell Calcium (2012)](https://pubmed.ncbi.nlm.nih.gov/22898249/)

[Kovács R, et al., NR2D-containing NMDA receptors in neuroprotection, Pharmacological Research (2020)](https://pubmed.ncbi.nlm.nih.gov/32061945/)

[Burnashev N, et al., NMDA receptor subunit composition in neurological disorders, Nature Reviews Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/34050396/)

[Henson MA, et al., NR2D subunits in memory and cognitive disorders, Learning & Memory (2015)](https://pubmed.ncbi.nlm.nih.gov/26553969/)

📖 View canonical wiki page →

Related Entities

GRIN2D

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-grin2d
kg_node_id	GRIN2D
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e6757134186e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-grin2d'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GRIN2D Protein

GRIN2D Protein

Introduction

GRIN2D Protein

Introduction

Structure and Domain Architecture

Extracellular Domains

Transmembrane Domains

Structural Features Unique to GluN2D

Normal Biological Function

Synaptic Transmission and Plasticity

Regional Distribution

Role in Neural Development

Extrasynaptic Signaling

Role in Neurodegenerative Diseases

Epilepsy

Parkinson's Disease

Alzheimer's Disease

Schizophrenia

Amyotrophic Lateral Sclerosis

Therapeutic Targeting

Drug Development Strategies

GluN2D-Selective Compounds

Clinical Applications

Mechanism-Based Approaches

Animal Models

Genetic Models

Disease Models

Biomarkers and Diagnostics

Clinical Applications

Research Biomarkers

Interaction Network

Protein-Protein Interactions

Signaling Pathways

Regulatory Mechanisms

Phosphorylation

Alternative Splicing

Comparison with Other GluN2 Subunits

Unique Properties of GRIN2D

Functional Implications

Clinical Significance

Diagnostic Considerations

Genetic Testing

Prognosis and Management

Research Directions

Emerging Therapeutic Approaches

Unanswered Questions

Pathophysiological Mechanisms

Excitotoxicity

Mitochondrial Dysfunction

Neuroinflammation

Pharmacological Modulation

Current Drug Targets

Challenges in Drug Development

Future Perspectives

Gene Therapy Approaches

Personalized Medicine

Biomarker Development

See Also

External Links

References

💬 Discussion